Peptide Library

Human study PLS-00129

Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds.

Other design · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds.primary · Lymphokine research · 1989-01-01 · PMID 2572736

Design and participants

Design
Other design
Population
Healthy adult volunteers experimentally infected with a rhinovirus strain (Hanks), in two groups of 18 and 20.
Conditions
Common cold (experimental rhinovirus infection)
Setting
Experimental rhinovirus challenge study
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
US Government (PHS) and non-US Government research support, per the publication types.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Rhinovirus infection raised serum thymosin alpha 1 and thymosin beta 4 levels and increased circulating T, CD8+ and NK cells. The authors suggest that local upper respiratory infection has systemic effects and induces cellular immune responses.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta 4 was measured only as an endogenous serum level and was never administered as an intervention.
    • no control group: The abstract describes no uninfected control group; all volunteers were inoculated with rhinovirus.
    • abstract only: Only the abstract is available, so methods and full results cannot be checked.
    • inappropriate endpoint: Thymosin beta 4 was measured as an endogenous biomarker and was not given as an intervention, so the study cannot show effects or safety of administration.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 2572736, abstract (final sentence) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 2572736, abstract (sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 2572736, title (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 2572736, abstract (sentences 2-3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 2572736, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).